Diagnostics & biomarkers

ALS Immunotherapy Moves Into the Extension Phase

Europe’s AMR Strategy Depends on the Lab Result Being Right

AMR Stewardship Starts Before the Antibiotic Is Prescribed

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment

Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race

J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
